Skip to Main Content
Table 2

Protection against chemotherapy-induced myelosuppression

The mean and SE are shown for nadir blood counts as a percentage of baseline.
Treatment No. of rats White cell nadir (%) Granulocyte nadir (%) Platelet nadir (%) 
No protectant 6 24.5 ± 5.8 20.7 ± 11.0 22.7 ± 8.7 
NAC i.v. postchemotherapy 6 46.0 ± 6.5a 57.9 ± 8.8a 36.8 ± 10.4 
NAC i.v. 30 min prior to chemotherapy 8 51.4 ± 9.4 93.5 ± 28.1 53.3 ± 12.7 
NAC aortic infusion postchemotherapy 6 25.9 ± 4.9 36.6 ± 17.0 26.8 ± 9.3 
NAC aortic infusion 30 min prior to chemotherapy 6 69.7 ± 19.3a 206 ± 125a 59.3 ± 17.9 
NAC aortic infusion 30 min prior + STS postchemotherapy 6 53.8 ± 12.8* 83.4 ± 21.3* 47.0 ± 11.5 
The mean and SE are shown for nadir blood counts as a percentage of baseline.
Treatment No. of rats White cell nadir (%) Granulocyte nadir (%) Platelet nadir (%) 
No protectant 6 24.5 ± 5.8 20.7 ± 11.0 22.7 ± 8.7 
NAC i.v. postchemotherapy 6 46.0 ± 6.5a 57.9 ± 8.8a 36.8 ± 10.4 
NAC i.v. 30 min prior to chemotherapy 8 51.4 ± 9.4 93.5 ± 28.1 53.3 ± 12.7 
NAC aortic infusion postchemotherapy 6 25.9 ± 4.9 36.6 ± 17.0 26.8 ± 9.3 
NAC aortic infusion 30 min prior to chemotherapy 6 69.7 ± 19.3a 206 ± 125a 59.3 ± 17.9 
NAC aortic infusion 30 min prior + STS postchemotherapy 6 53.8 ± 12.8* 83.4 ± 21.3* 47.0 ± 11.5 
a

P < 0.05 compared with no protectant by Wilcoxon/Kruskal-Wallis rank-sums test.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept